Download App

Log in to access Online Inquiry
Company Overview More
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
CEO: Butler, Thomas Andrew
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > BMEA Biomea Fusion > Detailed Quotes

BMEA Biomea Fusion

6.100+0.910+17.53%
Trading Session 05/19 14:52 ET
High
6.100
Open
5.180
Turnover
1.15M
Low
5.180
Pre Close
5.190
Volume
202.07K
Market Cap
177.93M
P/E(TTM)
Loss
52wk High
21.480
Shares
29.17M
P/E(Static)
Loss
52wk Low
2.840
Float Cap
91.85M
Bid/Ask %
-33.33%
Historical High
22.220
Shs Float
15.06M
Volume Ratio
0.51
Historical Low
2.840
Dividend TTM
--
Div Yield TTM
--
P/B
1.00
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.34%
Amplitude
17.73%
Avg Price
5.713
Lot Size
1
Float Cap
91.85M
Bid/Ask %
-33.33%
Historical High
22.220
Shs Float
15.06M
Volume Ratio
0.51
Historical Low
2.840
Dividend TTM
--
P/B
1.00
Dividend LFY
--
Turnover Ratio
1.34%
Amplitude
17.73%
Avg Price
5.713
Lot Size
1
Price Forecast

No Data

News

Comment